The U.S. Food and Drug Administration (FDA) last month approved leuprolide acetate for injectable suspension for the treatment of pediatric patients two years of age and older with central precocious puberty (CPP). Tolmar Pharmaceuticals is marketing the drug as Fensolvi. Leuprolide acetate is the most widely used treatment for CPP. Fensolvi utilizes a proprietary polymeric gel […]
TOPICS IN THIS ARTICLE:
